Immutep Limited (IMMP)
NASDAQ: IMMP · Real-Time Price · USD
1.720
-0.020 (-1.15%)
At close: Aug 1, 2025, 4:00 PM
1.750
+0.030 (1.74%)
After-hours: Aug 1, 2025, 5:08 PM EDT
Accolade Employees
Immutep had 31 employees as of June 30, 2014.
Employees
31
Change
n/a
Growth
n/a
Revenue / Employee
$97,395
Profits / Employee
-$875,690
Market Cap
246.29M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Jun 30, 2014 | 31 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IMMP News
- 2 days ago - Immutep Quarterly Activities Report Q4 FY25 - GlobeNewsWire
- 3 days ago - Immutep to Present Pivotal TACTI-004 Trial in Progress Poster at the 2025 World Conference on Lung Cancer - GlobeNewsWire
- 2 months ago - Immutep's Efti with Radiotherapy & KEYTRUDA® (pembrolizumab) Meets Primary Endpoint in Phase II for Soft Tissue Sarcoma - GlobeNewsWire
- 2 months ago - Immutep Reports 61% Response Rate In Lung Cancer Trial With Keytruda-Based Triple Combo - Benzinga
- 3 months ago - Immutep Limited: Surging On Positive Head And Neck Data - Seeking Alpha
- 4 months ago - Immutep to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 6 months ago - Immutep Quarterly Activities Report Q2 FY25 - GlobeNewsWire
- 6 months ago - Immutep Limited: Continuing To Make The Case For Eftilagimod - Seeking Alpha